Jumper
Student
- Jun 18, 2019
- 149
One would wonder why those diagnosed with psychiatric disorders; are not tested for this, but it's no surprise really, the profits for antipsychotics make more money.
Prevalence of bipolar disorder in the US:
— 5.3 million people
Prevalence of schizophrenia in the US:
— 3.2 million people
Prevalence of a depressive episode in the US:
— 17.3 million people
Cost of the anti-NMDA receptor antibody test: $85-$890
Prevalence of anti-NMDA receptor encephalitis: only 600-700 cases have ever been described.
Does not make sense to spend >2.6 billion dollars to screen psych patients, in order to identify < 0.002% that may have this. That's why they use a combination of strategies (involving story of symptoms) to identify those that need to be tested.
The makers of the test could make billions if so. Also, the treatment for NMDA receptor encephalitis is very expensive (not the steroids, but IVIG/Plasmapheresis/Rituxan)... so those companies could still financially benefit.